Farallon Capital Portfolio
Invests via Farallon Capital Management LLC | Managed by Farallon Capital Management LLC
Invests via Farallon Capital Management LLC
Managed by Farallon Capital Management LLC
Automatically Tracked
Company Profile
Founded in 1986 by Tom Steyer, Farallon Capital is a San Francisco-based alternative asset manager focused on value-oriented investing across public and private markets. The firm deploys multi-strategy capital into equities, credit, distressed, real assets and private equity alongside opportunistic special-situations investments. Institutional-facing, Farallon positions itself as a long-horizon, research-driven allocator that blends fundamental analysis with event-driven and relative-value tactics.
Founded in 1986 by Tom Steyer, Farallon Capital is a San Francisco-based alternative asset manager focused on value-oriented investing across public and private markets. The firm deploys multi-strategy capital into equities, credit, distressed, real assets and private equity alongside opportunistic special-situations investments. Institutional-facing, Farallon positions itself as a long-horizon, research-driven allocator that blends fundamental analysis with event-driven and relative-value tactics.
Investment Philosophy & Strategy
A long-horizon, multi-strategy allocator that emphasizes value-oriented, research-driven capital deployment across public and private markets. The approach blends fundamental equity and credit analysis with opportunistic distressed, event-driven and relative-value tactics to generate asymmetric returns. Capital allocation favors flexible positioning—strategic stakes in undervalued companies, credit exposures in stressed credits, real-asset hedges, and private investments where mispricing and operational upside exist. Risk management is active and portfolio-level, using diversification, liquidity overlays and position-sizing to protect capital while exploiting dislocations and special situations.
A long-horizon, multi-strategy allocator that emphasizes value-oriented, research-driven capital deployment across public and private markets. The approach blends fundamental equity and credit analysis with opportunistic distressed, event-driven and relative-value tactics to generate asymmetric returns. Capital allocation favors flexible positioning—strategic stakes in undervalued companies, credit exposures in stressed credits, real-asset hedges, and private investments where mispricing and operational upside exist. Risk management is active and portfolio-level, using diversification, liquidity overlays and position-sizing to protect capital while exploiting dislocations and special situations.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
97.11%
Gain +0.37%
Monthly
0.78%
Yearly
9.76%
Drawdown
19.48%
$18.62B
Equity
Holdings
$18.62B
Investment
$12.53B
$20.92B
Profit +$62.89M
Realized
$14.82B
Unrealized
$6.09B
Dividends
$1.41B
Goals
Avg. 99.25% completed goals
Yearly
Gain > 8% 2026
Yearly
Loss < 12% 2026
Yearly
Loss < $100M 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.37%
Profit
$62.89M
Win %
68%
This Week
Compared To Last Week
Gain
-0.8%
Profit
-$149.52M
Win %
68%
This Month
Compared to last month
Gain
-1.31%
Profit
-$247.5M
Win %
68%
This Year
Compared to last year
Gain
7.75%
Profit
$1.34B
Win %
66%
ANNAW Aleanna Inc.
+26.34%
+$48,510 
NERV Minerva Neurosciences Inc.
+4.26%
+$451,715 
ANNA Aleanna Inc.
+3.73%
+$9,016 
KKR KKR & Co. Inc.
+3.08%
+$13.51M 
ABVX Abivax SA ADR
+2.85%
+$386,740 
RVMDW Revolution Medicines, Inc. Warrant
+2.84%
+$39,628.05 
MSFT Microsoft Corp.
+2.81%
+$15.51M 
BBNX Beta Bionics Inc.
+2.34%
+$270,725 
BTSGU BrightSpring Health Services, Inc. 6.75% Preferred Stock due 2027
+2.26%
+$7.77M 
AZN AstraZeneca PLC American Depositary Shares
+1.71%
+$1.58M 
AMZN Amazon.com Inc
+1.59%
+$10.66M 
TMO Thermo Fisher Scientific Inc.
+1.54%
+$9.84M 
PTGX Protagonist Therapeutics Inc.
+1.46%
+$13.55M 
BIDU Baidu Inc.
+1.38%
+$1.57M 
NVO Novo Nordisk A/S Sponsored ADR
+1.38%
+$1.69M 
VNET VNET Group Inc. American Depositary Receipt
+1.36%
+$164,937.6 
TNGX Tango Therapeutics Inc.
+1.34%
+$3.68M 
WAY Waystar Holding Corp.
+1.17%
+$79,893.84 
EXEL Exelixis Inc.
+1.12%
+$8.82M 
COGT Cogent Biosciences, Inc.
+0.96%
+$5,638.9 
JNJ Johnson & Johnson
+0.91%
+$1.02M 
WELL Welltower Inc.
+0.9%
+$2,140 
ACHC Acadia Healthcare Company, Inc.
+0.75%
+$882,569.28 
RVMD Revolution Medicines Inc.
+0.69%
+$19.45M 
ALVO Alvotech SA
+0.66%
+$100,088.62 
BIIB Biogen Inc.
+0.62%
+$97,980 
ALMR Alamar Biosciences, Inc.
+0.54%
+$76,378.5 
ARMK Aramark
+0.54%
+$1.11M 
NTRA NATERA INC (Common Stock) – ticker 45E
+0.49%
+$3.52M 
GRAL Grail, Inc.
+0.4%
+$1.33M 
BGLWW Blue Gold Limited Warrant
+0.36%
+$25.58 
UNH UnitedHealth Group Incorporated
+0.34%
+$1.75M 
AXTA Axalta Coating Systems Ltd.
+0.34%
+$57,360 
WAB Wabtec Corporation
+0.11%
+$268,350.9 
NVS Novartis AG Sponsored ADR
+0.1%
+$61,710 
LNTH Lantheus Holdings, Inc.
+0.07%
+$390,843.53 
MRK Merck & Co., Inc.
+0.07%
+$19,901.99 
JOYY JOYY Inc. American Depositary Shares
+0.05%
+$27,968 
RIO Rio Tinto Plc Sponsored ADR
+0.01%
+$1,834.75 
ENTA Enanta Pharmaceuticals Inc.
0%
+$1,209.1 
CRNX Crinetics Pharmaceuticals Inc.
0%
$0 
EA Electronic Arts Inc.
0%
$0 
NVNIW Nvni Group Ltd. Warrant
0%
$0 
PCSC Perceptive Capital Solutions, Inc.
0%
$0 CGC
CGC
0%
$0 5949
594972AN1
0%
$0 5949
594972AS0
0%
$0 
JATT JATT II Acquisition Corp
0%
$0 9013
90138AAE3
0%
$0 5949
594972AU5
0%
$0 
GERN Geron Corporation
-5.66%
-$1,296 
IFRX InflaRx N.V.
-4.41%
-$335,492.5 
AGIO Agios Pharmaceuticals Inc.
-3.2%
-$6.47M 
BSX Boston Scientific Corporation
-3.02%
-$15.36M 
MOBI Mobia Medical, Inc.
-2.9%
-$394,994.95 
BC Brunswick Corporation
-2.82%
-$128,100 
MAZE Maze Therapeutics Inc.
-2.78%
-$821,665.64 
TEVA Teva Pharmaceutical Industries Ltd. ADR
-2.61%
-$39,200 
ASMB Assembly Biosciences Inc.
-2.29%
-$1.35M 
AVGO Broadcom Inc.
-2.19%
-$9.28M 
AVTX Avalo Therapeutics Inc.
-2.12%
-$1.02M 
NTES NetEase, Inc. American Depositary Receipt
-2.08%
-$307,515 
LQDA Liquidia Corporation
-2.07%
-$12.05M 
TSHA Taysha Gene Therapies Inc.
-2.04%
-$258,750 
BYND Beyond Meat Inc.
-1.99%
-$144.21 
TWST Twist Bioscience Corporation
-1.95%
-$5.46M 
KLRA Kailera Therapeutics, Inc.
-1.83%
-$319,000 
IDXX IDEXX Laboratories, Inc.
-1.76%
-$85,545.09 
IMVT Immunovant Inc.
-1.6%
-$3.68M 
BBIO BridgeBio Pharma, Inc.
-1.49%
-$12.25M 
WRBY Warby Parker Inc.
-1.38%
-$273,240 
SGMT Sagimet Biosciences Inc.
-1.33%
-$60,714.5 
GH Guardant Health Inc.
-1.31%
-$689,507.36 
SMG Scotts Miracle-Gro Co.
-1.25%
-$66,000 
PACB Pacific Biosciences of California, Inc.
-1.14%
-$213 
SMC Summit Midstream Corporation
-0.92%
-$18,628.48 
SNPS Synopsys, Inc.
-0.67%
-$2.3M 
BEAM Beam Therapeutics Inc.
-0.65%
-$1.95M 
AON Aon plc
-0.62%
-$2.83M 
CMC Commercial Metals Company
-0.59%
-$27,470 
RANI Rani Therapeutics Holdings Inc.
-0.41%
-$72.45 
SLDPW Solid Power, Inc. Warrant
-0.33%
-$40.53 
PRME Prime Medicine Inc.
-0.27%
-$12,408.43 
ROIV Roivant Sciences Ltd
-0.15%
-$742,637.1 
GNTX Gentex Corporation
-0.11%
-$4,975 
PBLS Parabilis Medicines, Inc.
-0.03%
-$26,287.02 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 9147 | Longs Won 4555/9147 49% | Profit Factor 2.63 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $18.34M |
| Average Win $7.41M | Best Trade (Aug 20) $634.45M | Sharpe Ratio -107.37 |
| Average Loss -$2.79M | Worst Trade (Dec 30) -$562.55M | Z-Score -13.36 (100%) |
| Commissions $0 | Avg. Trade Length 1y 4w | Expectancy $2.29M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 6,667 | 6,000 | 5,333 | 4,667 | 4,000 | 3,333 | 2,667 | 2,000 | 1,333 | 667 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 5949 594972AN1 | 15M | $14.19M | $14.19M | - | - | - | 0.0 |
| 5949 594972AS0 | 87.86M | $74.36M | $73.13M | - | -$1.23M | -1.66% | 0.0 |
| 5949 594972AU5 | 2.63M | $2.32M | $2.32M | - | - | - | 0.0 |
| 9013 90138AAE3 | 45M | $44.52M | $44.52M | - | - | - | 0.0 |
| ABVX Abivax SA ADR | 122,000 | $16.16M | $13.94M | - | -$2.22M | -13.75% | +2.854% |
| ACHC Acadia Healthcare Company, Inc. | 4.22M | $113.98M | $118.01M | - | $4.03M | 3.54% | +0.754% |
| AGIO Agios Pharmaceuticals Inc. | 5.92M | $172.83M | $195.49M | - | $22.66M | 13.11% | -3.204% |
| ALMR Alamar Biosciences, Inc. | 462,900 | $12.54M | $14.19M | - | $1.65M | 13.16% | +0.541% |
| ALVO Alvotech SA | 2.86M | $13.65M | $15.37M | - | $1.72M | 12.57% | +0.655% |
| AMZN Amazon.com Inc | 2.63M | $589.1M | $682.02M | - | $92.92M | 15.77% | +1.588% |
| ANNA Aleanna Inc. | 78,400 | $531,552 | $250,488 | - | -$281,064 | -52.88% | +3.734% |
| ANNAW Aleanna Inc. | 990,000 | $138,600 | $232,650 | - | $94,050 | 67.86% | +26.344% |
| AON Aon plc | 1.38M | $491.88M | $454.63M | - | -$37.25M | -7.57% | -0.62% |
| ARMK Aramark | 3.63M | $126M | $206.76M | - | $80.75M | 64.09% | +0.538% |
| ASMB Assembly Biosciences Inc. | 1.6M | $41.79M | $57.57M | - | $15.79M | 37.78% | -2.288% |
| AVGO Broadcom Inc. | 1.15M | $366.18M | $413.71M | - | $47.53M | 12.98% | -2.193% |
| AVTX Avalo Therapeutics Inc. | 2.5M | $42.91M | $47.29M | - | $4.38M | 10.2% | -2.12% |
| AXTA Axalta Coating Systems Ltd. | 478,000 | $16.36M | $17.16M | - | $807,820 | 4.94% | +0.335% |
| AZN AstraZeneca PLC American Depositary Shares | 574,000 | $110.56M | $94.36M | - | -$16.2M | -14.66% | +1.708% |
| BBIO BridgeBio Pharma, Inc. | 10.74M | $465.12M | $809.6M | - | $344.48M | 74.06% | -1.49% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Farallon Capital?
The largest contributions to the portfolio's profits come from the following stocks: Alphabet Inc - $1.04B, Microsoft Corp - $868.06M, Wabtec Corporation - $557.25M, Visa Inc. Class A - $557.05M, and Salesforce Inc - $489.15M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Altaba Inc - $1.18B, CSE - $537.12M, Block, Inc - $222.76M, 54975p102 - $211.28M, and Clarivate Plc - $177.62M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Farallon Capital's portfolio generate?
The portfolio generates substantial dividend income, with a total of $1.41B earned over time. The largest contributors to dividend income include Corgi MU 2x Daily ETF - $163.05M, Veon Ltd - $138.53M, TransDigm Group Inc - $74.67M, Microsoft Corp - $63.69M, and Citigroup Inc - $51.26M. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Farallon Capital's monthly returns?
Farallon Capital's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Farallon Capital's strategy be considered aggressive or moderate?
Farallon Capital's strategy appears moderately aggressive. The portfolio shows a clear focus on growth, with noticeable volatility and risk exposure, although not to an extreme level. This type of strategy may appeal to users seeking higher returns while accepting meaningful fluctuations along the way.
Should beginners follow Farallon Capital's strategy?
Farallon Capital's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
